Scarica l'app Stockscreener
1.10
4.76%
0.05
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Scrip
Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3B - Philadelphia Business Journal
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com
Century Therapeutics ends collaboration with Bristol-Myers Squibb By Investing.com - Investing.com UK
Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat
Fmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Faces Termination of BMS Agreement - TipRanks
Century Therapeutics (NASDAQ:IPSC) Trading Down 4.3%Here's Why - MarketBeat
Likelihood of Approval and Phase Transition Success Rate ModelCNTY-101 in Systemic Lupus Erythematosus - GlobalData
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Century Therapeutics to Present at Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Casdin Capital, LLC Increases Stake in Century Therapeutics Inc - GuruFocus.com
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - The Manila Times
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MSN
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve
Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market - MyChesCo
Syncona Portfolio Ltd's Strategic Acquisition of Autolus Therape - GuruFocus.com
FMR LLC's Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MyChesCo
Century Therapeutics to Present Cutting-Edge Preclinical Data at 2024 ASH Annual Meeting - MSN
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo
William Blair Has Positive Estimate for IPSC FY2024 Earnings - Defense World
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates - MSN
FY2024 Earnings Estimate for IPSC Issued By HC Wainwright - Defense World
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
What Makes Century Therapeutics (IPSC) a New Buy Stock - Yahoo Finance
What is HC Wainwright's Forecast for IPSC FY2024 Earnings? - MarketBeat
William Blair Has Strong Estimate for IPSC FY2024 Earnings - MarketBeat
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MyChesCo
Chardan Capital Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price - MarketBeat
Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults - TipRanks
Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo
Century Therapeutics shares target cut, retains Buy rating on updated data - Investing.com UK
HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - MarketBeat
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Century Therapeutics COO sells $1,267 in stock - Investing.com
Century Therapeutics Reports Q3 Results & Strategic Updates - TipRanks
Century Therapeutics COO sells $1,267 in stock By Investing.com - Investing.com UK
Century Therapeutics earnings beat by $0.08, revenue topped estimates - Investing.com UK
InventHelp Inventor Develops Protective Accessory for Underwear (ASP-336) - Yahoo Finance
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - The Manila Times
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of - The Bakersfield Californian
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting - Yahoo Finance
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):